MiR-92a Inhibits the Progress of Osteosarcoma Cells and Increases the Cisplatin Sensitivity by Targeting Notch1

Figure 2

MiR-92a attenuates the tumourigenesis of osteosarcoma in vitro. (A) MTT assay was performed to study the effects of miR-92a on OG63 and HOS cells 1, 2, 3, 4, and 5 days after transfection of miR-92a mimics, mimic control, miR-92a inhibitor, and inhibitor control. (B) Wound healing assay of the OG63 and HOS cells transfected with miR-92a mimics, mimic control, miR-92a inhibitor, and inhibitor control. (C) Flow cytometry was used to detect the cell cycle of OG63 and HOS cells transfected with miR-92a mimics, mimic control, miR-92a inhibitor, and inhibitor control. (D) Transwell assay was used to evaluate the cell migration of of OG63 and HOS cells transfected with miR-92a mimics, mimic control, miR-92a inhibitor, and inhibitor control. Data represent mean ± SD. P < 0.05; P < 0.01.